Page 106 - Read Online

Alqahtani et al. Hepatoma Res 2020;6:58 I http://dx.doi.org/10.20517/2394-5079.2020.49 Page 15 of 18

64. Ward JW, Hinman AR. What is needed to eliminate hepatitis b virus and hepatitis C virus as global health threats. Gastroenterology
2019;156:297-310.
65. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, et al. Persistence of antibodies and immune memory to
hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010;28:730-6.
66. WHO. Global hepatitis report, 2017. Geneva, Switzerland: WHO; 2017.
67. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., European Association for the Study of the
Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.
68. Chiang CJ, Yang YW, Chen JD, You SL, Yang HI, et al. Significant reduction in end-stage liver diseases burden through the national viral
hepatitis therapy program in Taiwan. Hepatology 2015;61:1154-62.
69. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, et al. The risk of hepatocellular carcinoma decreases after the first 5 years
of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017;66:1444-53.
70. Li M, Lv T, Wu S, Wei W, Wu X, et al. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in
patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int 2020;14:105-14.
71. Goh MJ, Sinn DH, Kim S, Woo SY, Cho H, et al. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B.
Hepatology 2020;71:2023-32.
72. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic
review and meta-analysis. Gastroenterology 2013;144:323-32.
73. Jiang P, Mukthavaram R, Chao Y, Nomura N, Bharati IS, et al. In vitro and in vivo anticancer effects of mevalonate pathway modulation
on human cancer cells. Br J Cancer 2014;111:1562-71.
74. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF)
by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001;133:1172-80.
75. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin
Oncol 2012;30:623-30.
76. Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients
with chronic hepatitis B. JAMA Intern Med 2019;179:633-40.
77. Kern MA, Schubert D, Sahi D, Schöneweiss MM, Moll I, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2
inhibitors in human liver tumor cells. Hepatology 2002;36:885-94.
78. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival
in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A 2012;109:E2165-72.
79. Calvisi DF. Inhibition of hepatitis B virus-associated liver cancer by antiplatelet therapy: a revolution in hepatocellular carcinoma
prevention? Hepatology 2013;57:848-50.
80. Mancebo A, González-Diéguez ML, Cadahía V, Varela M, Pérez R, et al. Annual incidence of hepatocellular carcinoma among patients
with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol 2013;11:95-101.
81. Mahale P, Torres HA, Kramer JR, Hwang LY, Li R, et al. Hepatitis C virus infection and the risk of cancer among elderly US adults: a
registry-based case-control study. Cancer 2017;123:1202-11.
82. Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, et al. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic
hepatitis C patients after interferon-based therapy. Br J Cancer 2013;109:2481-8.
83. Kruse RL, Kramer JR, Tyson GL, Duan Z, Chen L, et al. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of
hepatitis C virus-infected patients. Hepatology 2014;60:1871-8.
84. Huang CF, Yeh ML, Huang CI, Lin YJ, Tsai PC, et al. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with
spontaneous and treatment-induced viral clearance. Oncotarget 2017;8:43925-33.
85. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C
virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9.
86. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with
and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004;164:2349-54.
87. López-Diéguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, et al; GESIDA 37/03-FIPSE 36465/03-NEAT IG5
Study Group. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS 2011;25:899-904.
88. Tovo CV, Becker SC, Almeida PR, Galperim B, Chaves S. Progression of liver fibrosis in monoinfected patients by hepatitis C virus and
coinfected by HCV and human immunodeficiency virus. Arq Gastroenterol 2013;50:19-22.
89. Puoti M, Prestini K, Putzolu V, Zanini B, Baiguera C, et al. HIV/HCV co-infection: natural history. J Biol Regul Homeost Agents
2003;17:144-6.
90. Salmon-Ceron D, Nahon P, Layese R, Bourcier V, Sogni P, et al; ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups. Human
Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular
Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients. Hepatology 2019;70:939-54.
91. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and
management. Ann Gastroenterol 2015;28:221-8.
92. Lee LP, Dai CY, Chuang WL, Chang WY, Hou NJ, et al. Comparison of liver histopathology between chronic hepatitis C patients and
chronic hepatitis B and C-coinfected patients. J Gastroenterol Hepatol 2007;22:515-7.
93. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, et al. Rate of incidence of hepatocellular carcinoma in patients with
compensated viral cirrhosis. Cancer 1999;85:2132-7.